Objective: To quantify decision regret in individuals who had undergone sacral neuromodulation (SNM). Secondary objectives evaluated for correlation of subjects' regret score with symptom relief, complications, device explant status, or military deployment status.
Methods: Each subject's decision regret was assessed via a telephone survey utilizing a validated decision regret tool, and regret scores were calculated. A score of 50 was utilized a cutoff, below which patients were deemed to have minimal regret while those scores above 50 were associated with significant decision regret. Comparative statistics were used to identify correlation between regret scores and patient outcomes and military deployment status.
Results: Out of 170 identified subjects, 96 completed the full survey. The mean age of study participants was 49.8 ± 14.5 years, and 58.3% of the participants were female. The average time from implant to survey was 64 months. The mean regret score for patients reporting symptom improvement with the device was 5.4 ± 9.2 (vs 44.1 ± 27.6 for those who did not report symptom improvement, P <.001). Regret scores for patients who had device complications were significantly higher than those who did not. At the time of the survey, 82.3% of subjects had the implant in place. Those subjects who underwent device explant had higher regret scores than those who retained their device.
Conclusion: Decision regret related to SNM appeared low. SNM adverse outcome variables (poor symptom improvement, device complications, and explanted device) were associated with significantly higher decision regret scores than those with more ideal outcomes, but overall decision regret was still low. Military deployment had no correlation with SNM regret.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.urology.2024.10.067 | DOI Listing |
Front Endocrinol (Lausanne)
January 2025
Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padova, Padua, Italy.
Background: Differentiated thyroid carcinoma is the most common endocrine neoplasm; several studies have shown that individuals perceive the disease as being more severe than it actually is, resulting in a reduced quality of life. The primary aim of this study is to assess the quality of life and perception of illness among patients admitted for radiometabolic therapy, post total thyroidectomy for differentiated thyroid carcinoma. The secondary aim is to identify which patient characteristics are associated with a lower quality of life in order to improve and personalize care.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Texas Medical Branch, Galveston, TX, USA.
Background: Depression, pain, and sleep problems commonly co-occur (overlap) among older adults. Data are lacking on the extent, pattern and sex/gender differences of overlap of these symptoms in adults aged ≥80 and living with dementia. Our objective was to examine patterns and sex/gender differences in overlapping depression-pain-sleep symptoms among older Mexican Americans with and without probable dementia.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil, Belo Horizonte, Minas Gerais, Brazil.
Background: Cognitive impairment (CI) is a major geriatric syndrome, leading to the loss of an individual's decision-making autonomy and representing a significant caregiving burden for families. It is commonly encountered in clinical practice and can be caused by dementia (major neurocognitive disorder), depression, delirium, or mental illness.
Methods: To assess the prevalence and primary causes of cognitive impairment (CI), as well as its correlation with other clinical conditions among bed-bound or home-bound elderly individuals from low-resource communities in Brazil, we carried out a cross-sectional study.
Alzheimers Dement
December 2024
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands.
Background: Communicating amyloid-status and the subsequent risk of future cognitive decline to individuals with Subjective Cognitive Decline (SCD) is complex. Insight into how individuals with SCD evaluate the disclosure process and its impact could help optimize current practice. Therefore, the aim of our study was to examine experiences with, and outcomes of, amyloid-PET disclosure in individuals with SCD over time.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!